-

$undefined

N/A

(N/A)

Adlai Nortye Biopharma :ANL

Location: | Industry: | Sector:

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

180.7M

Cash

97.99M

Avg Qtr Burn

-16.68M

Short % of Float

0.01%

Insider Ownership

6.96%

Institutional Own.

0.20%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Buparlisib/AN2025 + Paclitaxel Details Cancer, Head and neck squamous cell carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Buparlisib/AN2025 in comb w/chemoradiotherapy and radiotherapy Details Cancer, Rectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AN0025 + definitive chemoradiotherapy (dCRT) Details Cancer, Esophageal cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.